Skip to main content

Advertisement

SpringerLink
Log in

Risk factors for ethambutol optic toxicity

  • Original Paper
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

Context Optic neuropathy is a well-known complication of ethambutol therapy and usually manifests as a decrease in visual acuity, cecocentral scotomas, and deficits in color vision. Objective To support or disprove the hypothesis that a significant majority of patients who develop ocular toxicity while undergoing treatment for a mycobacterium infection do so after experiencing either a prolonged course or unusually high serum levels of ethambutol. Design Retrospective chart review (16 cases) and literature meta-analysis (54 cases). Results Many cases lacked important data, but none countered the hypothesis. Age, duration of ethambutol, and dose of ethambutol were positively correlated with risk of toxicity. Conclusions Given an understanding of the risk factors for ethambutol optic toxicity, there exists a rationale for an optimization of ethambutol dosing protocols that can maximize the therapeutic effect while minimizing the incidence of optic toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Center for Disease Control Division of Tuberculosis Elimination (2007) Trends in tuberculosis, 2006—United States. http://www.cdc.gov/tb/pubs/tbfactsheets/TBTrends.htm. Accessed July 2008

  2. American Thoracic Society, Centers of Disease Control and Prevention, and Infectious Diseases Society of America (2003) Treatment of tuberculosis. MMWR 52(No. RR-11):1–77

  3. Zafar A (2005) Toxic/nutritional optic neuropathy. http://www.emedicine.com/OPH/topic750.htm. Accessed July 2008

  4. Leibold J (1966) The ocular toxicity of ethambutol and it’s relation to dose. Ann N Y Acad Sci 135:904. doi:10.1111/j.1749-6632.1966.tb45532.x

    Article  CAS  PubMed  Google Scholar 

  5. Fang JT, Chen YC, Chang MY (2004) Ethambutol-induced optic neuritis in patients with end stage renal disease on hemodialysis: two case reports and literature review. Ren Fail 26(2):189–193. doi:10.1081/JDI-120038521

    Article  PubMed  Google Scholar 

  6. Leppert D, Waespe W (1988) Neurotoxicity of antituberculous drugs in a patient without active tuberculosis. Ital J Neurol Sci 9(1):31–34

    Article  CAS  PubMed  Google Scholar 

  7. Petri WA Jr (2006) Goodman & Gilman’s the pharmacological basis of therapeutics, 11th edn, chap 47, sect 4. McGraw-Hill, New York

  8. Lindeman RD, Tobin J, Shock NW (1985) Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 33(4):278–285

    CAS  PubMed  Google Scholar 

  9. Schild HS, Fox BC (1991) Rapid-onset reversible ocular toxicity from ethambutol therapy. Am J Med 90(3):404–406. doi:10.1016/0002-9343(91)80028-K

    Article  CAS  PubMed  Google Scholar 

  10. Woung LC, Jou JR, Liaw SL (1995) Visual function in recovered ethambutol optic neuropathy. J Ocul Pharmacol Ther 11(3):411–419

    Article  CAS  PubMed  Google Scholar 

  11. Melamud A, Kosmorsky GS, Lee MS (2003) Ocular ethambutol toxicity. Mayo Clin Proc 78(11):1409–1411

    Article  PubMed  Google Scholar 

  12. Ikeda A, Ikeda T, Ikeda N, Kawakami Y, Mimura O (2006) Leber’s hereditary optic neuropathy precipitated by ethambutol. Jpn J Ophthalmol 50(3):280–283. doi:10.1007/s10384-005-0308-7

    Article  PubMed  Google Scholar 

  13. Nasemann J, Zrenner E, Riedel KG (1989) Recovery after severe ethambutol intoxication–psychophysical and electrophysiological correlations. Doc Ophthalmol 71(3):279–292. doi:10.1007/BF00170977

    Article  CAS  PubMed  Google Scholar 

  14. DeVita EG, Miao M, Sadun AA (1987) Optic neuropathy in ethambutol-treated renal tuberculosis. J Clin Neuroophthalmol 7(2):77–86

    CAS  PubMed  Google Scholar 

  15. Lai TY, Chan WM, Lam DS, Lim E (2005) Multifocal electroretinogram demonstrated macular toxicity associated with ethambutol related optic neuropathy. Br J Ophthalmol 89(6):774–775. doi:10.1136/bjo.2004.058099

    Article  CAS  PubMed  Google Scholar 

  16. Petrera JE, Fledelius HC, Trojaborg W (1998) Serial pattern evoked potential recording in a case of toxic optic neuropathy due to ethambutol. Electroencephalogr Clin Neurophysiol 71(2):146–149

    Google Scholar 

  17. Smith LJ (1987) Should ethambutol be barred? J Clin Neuroophthalmol 7:84–86

    Google Scholar 

  18. Kardon RH, Morrisey MC, Lee AG (2006) Abnormal multifocal electroretinogram (mfERG) in ethambutol toxicity. Semin Ophthalmol 21(4):215–222. doi:10.1080/08820530600987454

    Article  PubMed  Google Scholar 

  19. Farnsworth TD (1975) 100-hue test in diagnosis of ethambutol-induced damage to optic nerve. Ophthalmologica 171:425–431

    Article  Google Scholar 

  20. Zoumalan CI, Agarwal M, Sadun AA (2005) Optical coherence tomography can measure axonal loss in patients with ethambutol-induced optic neuropathy. Graefes Arch Clin Exp Ophthalmol 243:410–416. doi:10.1007/s00417-004-1053-1

    Article  PubMed  Google Scholar 

  21. Narang RK, Varma BM (1979) Ocular toxicity of ethambutol (a clinical study). Indian J Ophthalmol 27(1):37–40

    CAS  PubMed  Google Scholar 

  22. Lim SA (2006) Ethambutol-associated optic neuropathy. Ann Acad Med Singapore 35(4):274–278

    PubMed  Google Scholar 

  23. Zoumalan CI, Sadun AA (2007) Optical coherence tomography can monitor reversible nerve-fibre layer changes in a patient with ethambutol-induced optic neuropathy. Br J Ophthalmol 91(6):839–840. doi:10.1136/bjo.2006.107326

    Article  PubMed  Google Scholar 

  24. Dotti MT, Plewnia K, Cardaioli E, Manneschi L, Rufa A, Alemà G, Federico A (1998) A case of ethambutol-induced optic neuropathy harbouring the primary mitochondrial LHON mutation at nt 11778. J Neurol 245(5):302–303. doi:10.1007/s004150050223

    Article  CAS  PubMed  Google Scholar 

  25. Karmon G, Savir H, Zevin D, Levi J (1979) Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment. Ann Ophthalmol 11(7):1013–1017

    CAS  PubMed  Google Scholar 

  26. De Marinis M (2001) Optic neuropathy after treatment with anti-tuberculous drugs in a subject with Leber’s hereditary optic neuropathy mutation. J Neurol 248(9):818–819. doi:10.1007/s004150170103

    Article  PubMed  Google Scholar 

  27. Nair VS, LeBrun M, Kass I (1980) Peripheral neuropathy associated with ethambutol. Chest 77(1):98–100. doi:10.1378/chest.77.1.98

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Doheny Eye Institute, Keck School of Medicine, University of Southern California, 1450 San Pablo Street, Los Angeles, CA, 90033, USA

    Katherine Anne Talbert Estlin & Alfredo A. Sadun

Authors
  1. Katherine Anne Talbert Estlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alfredo A. Sadun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine Anne Talbert Estlin.

Additional information

Neither author has any financial interest in any proprietary product or medicine discussed in this article. This study was approved by the appropriate ethics committees.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Talbert Estlin, K.A., Sadun, A.A. Risk factors for ethambutol optic toxicity. Int Ophthalmol 30, 63–72 (2010). https://doi.org/10.1007/s10792-009-9293-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-009-9293-z

Keywords

Search

Navigation